| Literature DB >> 33197449 |
Meng Pu1, Janice M Cho1, Scott A Cunningham2, Gaurav K Behera1, Sarah Becker1, Talal Amjad1, Kerryl E Greenwood-Quaintance2, Helena Mendes-Soares3, Yava Jones-Hall4, Patricio R Jeraldo3, Jun Chen5, Gary Dunny6, Robin Patel7, Purna C Kashyap8.
Abstract
The increasing incidence of primary and recurring Clostridioides difficile infections (CDI), which evade current treatment strategies, reflects the changing biology of C difficile. Here, we describe a putative plasmid-mediated mechanism potentially driving decreased sensitivity of C difficile to vancomycin treatment. We identified a broad host range transferable plasmid in a C difficile strain associated with lack of adequate response to vancomycin treatment. The transfer of this plasmid to a vancomycin-susceptible C difficile isolate decreased its susceptibility to vancomycin in vitro and resulted in more severe disease in a humanized mouse model. Our findings suggest plasmid acquisition in the gastrointestinal tract to be a possible mechanism underlying vancomycin treatment failure in patients with CDI, but further work is needed to characterize the mechanism by which plasmid genes determine vancomycin susceptibility in C difficile.Entities:
Keywords: Amidase; Antimicrobial Resistance; Cell Wall Peptidoglycan; Gram Positive
Year: 2020 PMID: 33197449 PMCID: PMC7878333 DOI: 10.1053/j.gastro.2020.10.046
Source DB: PubMed Journal: Gastroenterology ISSN: 0016-5085 Impact factor: 22.682